دورية أكاديمية
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
| العنوان: | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial |
|---|---|
| المؤلفون: | Mahaffey K. W., Jardine M. J., Bompoint S., Cannon C. P., Neal B., Heerspink H. J. L., Charytan D. M., Edwards R., Agarwal R., Bakris G., Bull S., Capuano G., De Zeeuw D., Greene T., Levin A., Pollock C., Sun T., Wheeler D. C., Yavin Y., Zhang H., Zinman B., Rosenthal N., Brenner B. M., Perkovic V., serviddio G |
| المساهمون: | Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Capuano, G., De Zeeuw, D., Greene, T., Levin, A., Pollock, C., Sun, T., Wheeler, D. C., Yavin, Y., Zhang, H., Zinman, B., Rosenthal, N., Brenner, B. M., Perkovic, V., Serviddio, G |
| سنة النشر: | 2019 |
| المجموعة: | Università degli Studi di Foggia: CINECA IRIS Institutional Research Information System |
| مصطلحات موضوعية: | canagliflozin, clinical trial, diabetes mellitu, primary prevention, renal insufficiency, chronic, secondary prevention, Cardiovascular Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Human, Kidney Failure, Male, Middle Aged, Placebo Effect, Proportional Hazards Model, Risk, Sodium-Glucose Transporter 2 Inhibitor, Treatment Outcome |
| الوصف: | Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease. Clinical Trial Registration: URL: https://www.clinicaltrials.govTest. Unique identifier: NCT02065791. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31291786; info:eu-repo/semantics/altIdentifier/wos/WOS:000483552900013; volume:140; issue:9; firstpage:739; lastpage:750; numberofpages:12; journal:CIRCULATION; http://hdl.handle.net/11369/392196Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071325197 |
| DOI: | 10.1161/CIRCULATIONAHA.119.042007 |
| الإتاحة: | https://doi.org/10.1161/CIRCULATIONAHA.119.042007Test http://hdl.handle.net/11369/392196Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F607F64E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/CIRCULATIONAHA.119.042007 |
|---|